1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Global CEO Grouping Lays Out Japan, Wider Priorities Ahead Of G7 Meeting

UHC, Access, Pricing In Spotlight

 
• By Ian Haydock and Lisa Takagi

The Biopharmaceutical CEO Roundtable has added a chorus of C-suite voices to ongoing calls for Japan reform discussions, while also flagging key global health agenda items for the upcoming G7 meeting in the country.

The BCR conference by IFMPA in Tokyo, Japan was joined by several government officials including the PM Fumio Kishida (center)
Japan BCR talks in Tokyo joined by officials including PM Fumio Kishida (center) • Source: IFMPA

During a recent visit to Japan ahead of the upcoming G7 Summit, members of the Biopharmaceutical CEO Roundtable (BCR) made another call on behalf of the research-based biopharma industry for the country’s government to set up a new strategic reform discussion on health and medicine issues.

“We respectfully propose that your government create a public-private Strategic Dialogue to discuss constructive proposals to strengthen Japan’s biopharmaceutical innovation ecosystem,” the global grouping of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By Lisa Takagi

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.